Thursday, February 09, 2017 8:53:02 AM
Hemoadsorption with Adult CytoSorb® in a Low Weight Pediatric Case – A Worldwide Premiere Procedure
Cirstoveanu C, Barascu I, Stancu A. Case Rep Crit Care. 2017;2017:6987167
This case study reports on the case of a nine-month-old male infant who was admitted to the neonatal intensive care unit from the pediatric cardiovascular surgery unit, on his fourth postoperative day after the correction of tetralogy of Fallot.
Case presentation
On the 3rd postop day the patient became febrile, so a complete blood count (CBC), biochemistry and a blood culture were performed. On day 4 he was admitted to the NICU gravely unwell, intubated and mechanically ventilated, with unilaterally diminished breath sounds, hypoxemia (oxygen saturation: 90%), oliguria, tachycardia (137 beats per minute), hypotension (74/44/59 mmHg) and abdominal distention with anasarca and fever (39-40oC). Physical examination revealed hepatosplenomegaly.
CBC showed hemoconcentration (Hb: 14.2 g/dl, Ht: 45%), thrombocytopenia (27,000/mm3), leukocytosis (17,800/mm3) with neutrophilia (66.6%). Coagulation tests revealed a grossly elevated INR (4.66), hypofibrinogenemia (113 mg/dl) and a prolonged aPPT time (63 seconds). A severe inflammatory response (SIRS) was noted (CRP: 47.76 U/L, Procalcitonin: 10 ng/L). Liver function tests (LFTs) were greatly abnormal (ALT: 1883.1 U/L, AST: 4214.5 U/L, GGT 72 U/L, total bilirubin: 10.05 mg/dl, direct bilirubin: 7.59 mg/dl), consistent with hepatocellular necrosis.
Renal impairment was evident with a creatinine of 1.15 mg/dl and urea of 55 mg/dl. Creatinine kinase and creatine kinase-MB were also elevated with values of 1619 U/L and 159.6 U/L, respectively. Acid-base balance was deranged (metabolic acidosis). Blood culture was sterile and the culture from tracheal aspirate revealed Escherichia coli.
Meropenem, Vancomycin and Fluconazole were initiated. Multiple episodes of severe hypotension and bradycardia were treated with adrenaline, noradrenaline and dopamine. Due to persistent SIRS (CRP values from 47.76 to 54.76), antibiotics were changed to Tienam (Imipenem and Cilastin) and Amikacin.
Two days after ICU admission oliguria rapidly evolved to anuria, and peritoneal dialysis was initiated. While the patient’s fluid intake continued to exceed the output the decision was made to start hemodiafiltration (HDF) (Prismaflex, Baxer). Throughout HDF, the patient continued to be hypotensive and bradycardic necessitating in an increased dose of inotropic agents.
Metabolic acidosis also persisted despite treatment, he continued to be thrombocytopenic requiring multiple thrombocyte mass transfusions. He also developed macrocytic, hyperchromic anemia. After initiation of HDF he continued to be oliguric with intensely hyperchromic hematuria.
As the patient continued to be febrile, antibiotic therapy was modified once more to Meropenem and Ciprofloxacin for a duration of 16 days. Antibotic doses were kept constant throughout.
Bilirubin levels kept increasing, culminating in a maximum value of 54 mg/dl of total bilirubin and 31.67 mg/dl of direct bilirubin. Intense scleral and cutaneous jaundice was observed and the patient was diagnosed with cholestatic jaundice.
On the 9th day of continuous hemodiafiltration the therapeutic decision of commencing hemadsorption with a cytokine adsorber (CytoSorb) was taken
Treatment
One treatment with CytoSorb for 49 hours
CytoSorb was used in conjunction with CRRT (Prismaflex, Baxter) performed in CVVHDF mode
Blood flow rate: 40 ml/min
Because of the flow rate being so much slower that the recommended flow rate, the procedure was maintained for 49 hours
Anticoagulation: heparin
CytoSorb adsorber position: post-hemofilter
Measurements
Demand for catecholamines (norepinephrine, dopamine, epinephrine)
Ventilation settings (FiO2, respiratory rate, positive end expiratory pressure (PEEP), positive inspiratory pressure (PIP))
Bilirubin, transaminases
Results
During the first 24-hour period with CytoSorb, total bilirubin value decreased from 54 to 17 mg/dl and the patient’s general status improved considerably. At the end of the 49 hours the total bilirubin was 14 mg/dl.
The liver function (aminotransferases) also decreased rapidly but rose to their previous values as soon as CytoSorb® was removed.
Noradrenaline decreased rapidly from 0.8 to 0.18 mcg/kg/min during the first 24 hrs and ceased within the next 24 hours. Dopamine decreased from 8 to 5 mcg/kg/min to 0 during liver support. The dose of adrenaline decreased within 48 hours of CytoSorb® treatment and ceased after 5 days.
The patient’s ventilation settings also improved during CytoSorb treatment
Patient Follow-Up
HDF was stopped after 11 days
The patient’s cardiovascular status improved
Diuresis gradually reached normal values and enteral nutrition could be initiated
Quantitative renal function returned to normal as did renal function tests
It was possible to keep the antibiotic doses constant during the entire CytoSorb procedure
The patient was discharged home after 34 days of hospitalization, in good general status, hemodynamically stable, afebrile and weighing 9.6 kilograms
He was referred to a pediatric neurologist for follow-up
CONCLUSIONS
This is the first published case of CytoSorb used in a critically unwell 9 month old baby
CytoSorb could be safely used in this pediatric case of septic multi-organ failure after cardiac surgery
Both bilirubin levels and liver enymes improved dramatically during CytoSorb use as did the patients hemodynamic and respiratory status
Despite the fact that the flow rate was only 40mls / min (normally >100-150 mls/min), there were no instances of clotting in the adsorber
Antibiotic doses could be kept constant during the entire hemoadsorption procedure using CytoSorb
Recent CTSO News
- CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference • GlobeNewswire Inc. • 08/27/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2024 08:51:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:58:42 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:57:45 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/16/2024 09:28:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 09:12:04 PM
- CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/16/2024 08:05:00 PM
- CytoSorbents Reports Second Quarter 2024 Financial and Operational Results • GlobeNewswire Inc. • 08/13/2024 08:19:55 PM
- CytoSorbents Appoints Peter J. Mariani Chief Financial Officer • GlobeNewswire Inc. • 08/13/2024 08:18:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:04:32 PM
- CytoSorbents to Report Second Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 08/07/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:12:56 PM
- CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 08/01/2024 11:00:00 AM
- CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website • GlobeNewswire Inc. • 07/29/2024 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/26/2024 09:14:03 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/26/2024 09:11:21 PM
- CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress • GlobeNewswire Inc. • 07/17/2024 11:00:00 AM
- CytoSorbents Secures $20 Million Credit Facility • GlobeNewswire Inc. • 07/02/2024 11:00:00 AM
- CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan • GlobeNewswire Inc. • 06/24/2024 11:00:00 AM
- CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union • GlobeNewswire Inc. • 06/13/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:31:20 PM
- CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting • GlobeNewswire Inc. • 06/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:35:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:23:00 PM
- CytoSorbents Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/09/2024 08:17:23 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM